Waters Corporation announced the launch of OligoWorks SPE (solid phase extraction) Kits and components to improve sample preparation for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides. Pharma and biopharma companies developing oligonucleotide therapeutics and the Contract Research Organizations (CROs) that support them can now realize up to a 2x increase over competing products in oligonucleotide recovery from biofluids. The Kits deliver greater reproducibility and LC-MS sensitivity, enabling lower limits of quantitation and reducing the need for repeat experiments.

The pipeline for oligonucleotide therapeutics is rapidly expanding with thirteen FDA approved oligonucleotide therapeutics today, and 500+ in the pipeline. While potent, these highly modified oligonucleotides are challenging to precisely quantify during dosing, metabolism, and tissue distribution studies. OligoWorks SPE Kits also use an innovative, enzyme-enhanced, and detergent-free sample pretreatment that reduces washing steps and improves mass spectrometer compatibility, thus enabling direct injection LC-MS analysis and lower limits of quantitation.

They can also be fully automated for improved productivity, or to simply help scientists gain back time by reducing manual steps and oversight. Available immediately, OligoWorks SPE Kits and components are another high-performance tool within the growing portfolio of Waters chemistry solutions to support oligonucleotide bioanalysis. They complement Waters best-selling MaxPeak Premier Columns, ACQUITY Premier LC System and Arc Premier LC System, Andrew+ Pipetting Robot, and the class-leading sensitivity of the Waters Xevo TQ Absolute Mass Spectrometer.